Melinta Therapeutics, Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes various anti-infectives for the treatment of bacterial infectious diseases in North America. It offers Baxdela, an antibiotic for the treatment of acute bacterial skin and skin structure infections (ABSSSI); Vabomere, a carbapenem used in treatment of gram-negative infections; Orbactiv, an antibiotic of the lipoglycopeptide class for the treatment of adult patients with ABSSSIs; and Minocin, a IV antibiotic of the tetracycline class with activity against gram-positive and gram-negative pathogens, as well as Solithromycin, a macrolide antibiotic for the treatment of CABP. The company also develops Baxdela that in a Phase III clinical trial for treating community-acquired bacterial pneumonia (CABP)); Fusidic Acid, which is in Phase III clinical trial for treating ABSSSIs; and radezolid, a melinta molecule that is in Phase II clinical trial for dermatological applications, as well as ESKAPE pathogen program, which is in preclinical stage targeting superbugs. Melinta Therapeutics, Inc. was formerly known as formerly Rib-X Pharmaceuticals, Inc. and changed its name to Melinta Therapeutics, Inc. in October 2013. The company was founded in 2000 and is headquartered in New Haven, Connecticut.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Phone908-617-1309
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$33.86 million
Profitability
Miscellaneous
Employees300
OptionableOptionable
Melinta Therapeutics (NASDAQ:MLNT) Frequently Asked Questions
What is Melinta Therapeutics' stock symbol?
Melinta Therapeutics trades on the NASDAQ under the ticker symbol "MLNT."
How were Melinta Therapeutics' earnings last quarter?
Melinta Therapeutics Inc (NASDAQ:MLNT) announced its earnings results on Tuesday, August, 7th. The biotechnology company reported ($1.38) earnings per share for the quarter, missing analysts' consensus estimates of ($1.14) by $0.24. The biotechnology company earned $12.02 million during the quarter, compared to the consensus estimate of $12.06 million. Melinta Therapeutics had a negative return on equity of 68.68% and a negative net margin of 202.31%. View Melinta Therapeutics' Earnings History.
When is Melinta Therapeutics' next earnings date?
What price target have analysts set for MLNT?
7 brokers have issued 12-month target prices for Melinta Therapeutics' shares. Their predictions range from $8.00 to $15.00. On average, they expect Melinta Therapeutics' share price to reach $12.5833 in the next twelve months. This suggests a possible upside of 773.8% from the stock's current price. View Analyst Price Targets for Melinta Therapeutics.
What is the consensus analysts' recommendation for Melinta Therapeutics?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Melinta Therapeutics in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Melinta Therapeutics.
Has Melinta Therapeutics been receiving favorable news coverage?
Media stories about MLNT stock have trended somewhat positive on Friday, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Melinta Therapeutics earned a coverage optimism score of 1.1 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 3.0 out of 10, meaning that recent media coverage is unlikely to have an impact on the stock's share price in the near term.
Are investors shorting Melinta Therapeutics?
Melinta Therapeutics saw a drop in short interest during the month of January. As of January 31st, there was short interest totalling 1,178,376 shares, a drop of 28.3% from the January 15th total of 1,644,462 shares. Based on an average trading volume of 397,029 shares, the short-interest ratio is currently 3.0 days. Currently, 3.3% of the shares of the company are sold short. View Melinta Therapeutics' Current Options Chain.
Who are some of Melinta Therapeutics' key competitors?
Some companies that are related to Melinta Therapeutics include Achillion Pharmaceuticals (ACHN), Tyme Technologies (TYME), Dermira (DERM), BioDelivery Sciences International (BDSI), Abeona Therapeutics (ABEO), Albireo Pharma (ALBO), American Brivision (Holding) (ABVC), Aclaris Therapeutics (ACRS), Verrica Pharmaceuticals (VRCA), XBiotech (XBIT), OptiNose (OPTN), Magenta Therapeutics (MGTA), Constellation Pharmaceuticals (CNST), Aduro BioTech (ADRO) and BIOFRONTERA AG/ADR (BFRA).
Who are Melinta Therapeutics' key executives?
Melinta Therapeutics' management team includes the folowing people:
- Dr. Erin M. Duffy Ph.d., Chief Scientific Officer (Age 51)
- Mr. John H. Johnson, CEO & Director (Age 61)
- Dr. Thomas A. Steitz Ph.D., Co-Founder
- Dr. Peter B. Moore Ph.D., Co-Founder
- Dr. William L. Jorgensen Ph.D., Co-Founder
Who are Melinta Therapeutics' major shareholders?
Melinta Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (4.52%), First Manhattan Co. (1.69%), Dimensional Fund Advisors LP (1.38%), Fosun International Ltd (0.88%), Geode Capital Management LLC (0.75%) and Two Sigma Investments LP (0.56%). Company insiders that own Melinta Therapeutics stock include David N Gill, Dov A Md Goldstein, Paul Estrem, Sue Cammarata and Vatera Healthcare Partners Llc. View Institutional Ownership Trends for Melinta Therapeutics.
Which major investors are selling Melinta Therapeutics stock?
Which major investors are buying Melinta Therapeutics stock?
MLNT stock was bought by a variety of institutional investors in the last quarter, including Fosun International Ltd, Two Sigma Investments LP, Assenagon Asset Management S.A., Boenning & Scattergood Inc., BlackRock Inc., Condor Capital Management, Dimensional Fund Advisors LP and Rhumbline Advisers. Company insiders that have bought Melinta Therapeutics stock in the last two years include David N Gill, Paul Estrem, Sue Cammarata and Vatera Healthcare Partners Llc. View Insider Buying and Selling for Melinta Therapeutics.
How do I buy shares of Melinta Therapeutics?
Shares of MLNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Melinta Therapeutics' stock price today?
One share of MLNT stock can currently be purchased for approximately $1.44.
How big of a company is Melinta Therapeutics?
Melinta Therapeutics has a market capitalization of $80.67 million and generates $33.86 million in revenue each year. The biotechnology company earns $-58,910,000.00 in net income (profit) each year or ($21.86) on an earnings per share basis. Melinta Therapeutics employs 300 workers across the globe.
What is Melinta Therapeutics' official website?
How can I contact Melinta Therapeutics?
Melinta Therapeutics' mailing address is 300 GEORGE STREET SUITE 301, NEW HAVEN CT, 06511. The biotechnology company can be reached via phone at 908-617-1309 or via email at [email protected]
MarketBeat Community Rating for Melinta Therapeutics (NASDAQ MLNT)
MarketBeat's community ratings are surveys of what our community members think about Melinta Therapeutics and other stocks. Vote "Outperform" if you believe MLNT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MLNT will underperform the S&P 500 over the long term. You may vote once every thirty days.
